Based in San Diego, California, DexCom designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic health management. The company's primary product portfolio includes the Dexcom G7 and G7 15 Day integrated CGM systems, the Dexcom G6, and Dexcom ONE+, which enables users to replace traditional fingerstick blood glucose testing. The company also offers Stelo, a biosensor targeting adults with prediabetes and Type 2 diabetes who do not use insulin, alongside remote monitoring solutions through Dexcom Share and the Dexcom Follow application.
DexCom markets its products directly to endocrinologists, physicians, and diabetes educators. The company operates across both the United States and international markets, with a workforce of approximately 11,000 full-time employees. Revenue streams are generated primarily through the sale of CGM devices and related monitoring systems to healthcare providers and patients, though specific segment breakdowns are not publicly detailed.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $2.09 | $2.14 | +47.2% | |
| 2024 | $1.42 | $1.46 | +9.2% | |
| 2023 | $1.30 | $1.40 | +58.5% | |
| 2022 | $0.82 | $0.88 | -47.1% | |
| 2021 | $1.55 | $1.60 | -69.4% | |
| 2020 | $5.06 | $5.23 | +406.0% | |
| 2019 | $1.00 | $1.01 | +149.3% | |
| 2018 | $-2.03 | $-2.03 | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-12 | 0001093557-26-000027 | SEC ↗ |
| 2024-12-31 | 2025-02-18 | 0001093557-25-000036 | SEC ↗ |
| 2023-12-31 | 2024-02-08 | 0001093557-24-000021 | SEC ↗ |
| 2022-12-31 | 2023-02-09 | 0001093557-23-000024 | SEC ↗ |
| 2021-12-31 | 2022-02-14 | 0001093557-22-000014 | SEC ↗ |
| 2020-12-31 | 2021-02-11 | 0001093557-21-000024 | SEC ↗ |
| 2019-12-31 | 2020-02-13 | 0001093557-20-000029 | SEC ↗ |
| 2018-12-31 | 2019-02-21 | 0001093557-19-000041 | SEC ↗ |